Adverse effects of bevacizumab and their management in solid tumors

Yull Arriaga, Carlos R. Becerra

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Bevacizumab is the first successful example of targeting the vasculature for the treatment of solid tumors. Although generally well tolerated in combination with different chemotherapy regimens, bevacizumab has side effects that are unique to this class of agents. In this review, we discuss the side effects associated with bevacizumab and potential treatments to ameliorate these toxicities.

Original languageEnglish (US)
Pages (from-to)247-250
Number of pages4
JournalSupportive Cancer Therapy
Volume3
Issue number4
DOIs
StatePublished - Jul 2006

Fingerprint

Neoplasms
Drug Therapy
Therapeutics
Bevacizumab

Keywords

  • Bleeding
  • Gastrointestinal perforations
  • Hypertension
  • Proteinuria
  • Thrombosis
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology

Cite this

Adverse effects of bevacizumab and their management in solid tumors. / Arriaga, Yull; Becerra, Carlos R.

In: Supportive Cancer Therapy, Vol. 3, No. 4, 07.2006, p. 247-250.

Research output: Contribution to journalArticle

Arriaga, Yull ; Becerra, Carlos R. / Adverse effects of bevacizumab and their management in solid tumors. In: Supportive Cancer Therapy. 2006 ; Vol. 3, No. 4. pp. 247-250.
@article{7ab92d05806d4c649bd42062d7ae6e96,
title = "Adverse effects of bevacizumab and their management in solid tumors",
abstract = "Bevacizumab is the first successful example of targeting the vasculature for the treatment of solid tumors. Although generally well tolerated in combination with different chemotherapy regimens, bevacizumab has side effects that are unique to this class of agents. In this review, we discuss the side effects associated with bevacizumab and potential treatments to ameliorate these toxicities.",
keywords = "Bleeding, Gastrointestinal perforations, Hypertension, Proteinuria, Thrombosis, Vascular endothelial growth factor",
author = "Yull Arriaga and Becerra, {Carlos R.}",
year = "2006",
month = "7",
doi = "10.3816/SCT.2006.n.023",
language = "English (US)",
volume = "3",
pages = "247--250",
journal = "Supportive Cancer Therapy",
issn = "1543-2912",
publisher = "Cancer Information Group, LP",
number = "4",

}

TY - JOUR

T1 - Adverse effects of bevacizumab and their management in solid tumors

AU - Arriaga, Yull

AU - Becerra, Carlos R.

PY - 2006/7

Y1 - 2006/7

N2 - Bevacizumab is the first successful example of targeting the vasculature for the treatment of solid tumors. Although generally well tolerated in combination with different chemotherapy regimens, bevacizumab has side effects that are unique to this class of agents. In this review, we discuss the side effects associated with bevacizumab and potential treatments to ameliorate these toxicities.

AB - Bevacizumab is the first successful example of targeting the vasculature for the treatment of solid tumors. Although generally well tolerated in combination with different chemotherapy regimens, bevacizumab has side effects that are unique to this class of agents. In this review, we discuss the side effects associated with bevacizumab and potential treatments to ameliorate these toxicities.

KW - Bleeding

KW - Gastrointestinal perforations

KW - Hypertension

KW - Proteinuria

KW - Thrombosis

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33749464563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749464563&partnerID=8YFLogxK

U2 - 10.3816/SCT.2006.n.023

DO - 10.3816/SCT.2006.n.023

M3 - Article

C2 - 18632501

AN - SCOPUS:33749464563

VL - 3

SP - 247

EP - 250

JO - Supportive Cancer Therapy

JF - Supportive Cancer Therapy

SN - 1543-2912

IS - 4

ER -